Da läuft einiges bei $CHRS (+0.66%)
----
Big news! Our parent company, Intas Pharmaceuticals, Ltd. has signed an agreement to acquire the UDENYCA® (pegfilgrastim-cbqv) business from
. We look forward to next steps as we work to expand our portfolio of patient-centered therapies across our therapeutic areas of focus. Learn more: http://prn.to/3B8FybY
